- Home
- SIGA vs NCZ Comparison
SIGA vs NCZ Comparison
Compare SIGA & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SIGA | NCZ |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.0M | 282.2M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SIGA | NCZ |
|---|---|---|
| Price | $4.20 | $15.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 427.2K | 78.9K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 13.24% | 12.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $224.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $11.90 |
| 52 Week High | $9.62 | $15.90 |
Technical Indicators
Market Signals| Indicator | SIGA | NCZ |
|---|---|---|
| Relative Strength Index (RSI) | 32.55 | 55.94 |
| Support Level | N/A | $13.59 |
| Resistance Level | $4.80 | N/A |
| Average True Range (ATR) | 0.17 | 0.26 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 17.58 | 53.04 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of current income, current gains and long-term capital appreciation. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.